SJB3-019A (SJB-019) is a novel and potent USP1 (Ubiquitin-specific protease 1) inhibitor, promoting ID1 degradation and cytoxicity in K562 cells with IC50 of 0.0781 μM.
Physicochemical Properties
| Molecular Formula | C16H8N2O3 |
| Molecular Weight | 276.24632358551 |
| Exact Mass | 276.053 |
| CAS # | 2070015-29-9 |
| PubChem CID | 78358325 |
| Appearance | Light yellow to yellow solid powder |
| Density | 1.426±0.06 g/cm3(Predicted) |
| Boiling Point | 526.1±52.0 °C(Predicted) |
| LogP | 2.5 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 1 |
| Heavy Atom Count | 21 |
| Complexity | 453 |
| Defined Atom Stereocenter Count | 0 |
| InChi Key | DOYPPVCQHGJUBC-UHFFFAOYSA-N |
| InChi Code | InChI=1S/C16H8N2O3/c19-13-10-5-1-2-6-11(10)14(20)15-12(13)18-16(21-15)9-4-3-7-17-8-9/h1-8H |
| Chemical Name | 2-pyridin-3-ylbenzo[f][1,3]benzoxazole-4,9-dione |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | Compared to SJB2-043, SJB3-019A (IC50=0.0781 μM) had five times the potency in stimulating ID1 degradation and cytotoxicity in K562 cells. SJB3-019A lowers HR activity while raising Ub-FANCD2 and Ub-PCNA levels [1]. |
| References |
[1]. Small molecule inhibitors of USP1 target ID1 degradation in leukemic cells. Mol Cancer Ther Published OnlineFirst October 15, 2013. |
Solubility Data
| Solubility (In Vitro) | DMSO : ~10 mg/mL (~36.20 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1 mg/mL (3.62 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.6199 mL | 18.0995 mL | 36.1991 mL | |
| 5 mM | 0.7240 mL | 3.6199 mL | 7.2398 mL | |
| 10 mM | 0.3620 mL | 1.8100 mL | 3.6199 mL |